Trial Profile
A Multicenter, 12 Week, Double-blind, Placebo-controlled, Randomized Withdrawal Study To Determine The Efficacy And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Subjects With Moderate To Severe Chronic Low Back Pain
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Oxycodone/naltrexone (Primary)
- Indications Back pain
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 19 Aug 2016 According to a Pfizer media release, the US FDA has approved Troxyca ER (oxycodone/naltrexone) for oral use, with the abuse-deterrent properties for the management of pain.
- 28 Apr 2015 According to a Pfizer media release, the US FDA has assigned a PDUFA action date in October 2015 for the NDA for oxycodone/naltrexone [ALO 02] for the treatment of severe pain.
- 03 May 2014 Results presented at the 33rd Annual Scientific Meeting of the American Pain Society.